Does garlic have a role as an antidiabetic agent?

Molecular Nutrition and Food Research

Volumn 51, Issue 11, 2007, Pages 1353-1364

  Liu, Cheng Tzu ^a   Sheen, Lee Yan ^b   Lii, Chong Kuei ^a  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Antidiabetic activity; Diabetes complications; Garlic; Hypoglycemic activity; Insulin secretagogue

Indexed keywords

ANTIDIABETIC AGENT; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; INSULIN;

ANIMAL; ARTICLE; CHEMISTRY; DIABETES MELLITUS; GARLIC; HUMAN; PHYTOTHERAPY; SECRETION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; DIABETES COMPLICATIONS; DIABETES MELLITUS; GARLIC; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; PHYTOTHERAPY;

ALLIUM SATIVUM; ANIMALIA;

EID: 36649035056     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.200700082     Document Type: Article

References (133)

1. King, H., Aubert, R. E., Herman, W. H., Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections, Diabetes Care 1998, 21, 1414-1431.
2. No authors listed, The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group N. Engl. J Med. 1993, 329, 977-986.
3. No authors listed, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group, Lancet 1998, 352, 837-853.
4. Stettier, C., Allemann, S., Juni, P., Cull, C. A., et al., Glycemic control and macrovascular disease in type 1 and 2 diabetes mellitus: Meta-analysis of randomized trials, Am. Heart J. 2006, 152, 27-38.
5. Kirkman, M. S., McCarren, M., Shah, J., Duckworth, W., et al., The association between metabolic control and prevalent macrovascular disease in type 2 diabetes: The VA Cooperative Study in diabetes, J. Diabet. Complications 2006, 20, 75-80.
6. No authors listed, WHO Expert Committee on Diabetes Mellitus: second report. World Health Organ. Tech. Rep. Ser. 1980, 645, 1-54.
7. Rivlin, R. S., Is garlic alternative medicine? J Nutr. 2006, 136, 713S-715S.
8. Bhagyalakshmi, N., Thimmaraju, R., Venkatachalam, L., Murthy, K. N., Sreedhar, R. V., Nutraceutical applications of garlic and the intervention of biotechnology, Crit. Rev. Food Sci. Nutr. 2005, 45, 607-621.
9. Morris, C. A., Avorn, J., Internet marketing of herbal products, JAMA 2003, 290, 1505-1597.
10. Blumenthal, M., Herbs continue slide in mainstream market: Sales down 14 percent, Herbal Gram 2003, 58, 71.
11. Banerjee, S. K., Mukherjee, P. K., Maulik, S. K., Garlic as an antioxidant: the good, the bad and the ugly, Phytother. Res. 2003, 17, 97-106.
12. Ariga, T., Seki, T., Antithrombotic and anticancer effects of garlic-derived sulfur compounds: a review, Biofactors 2006, 26, 93-103.
13. El-Bayoumy, K., Sinha, R., Pinto, J. T., Rivlin, R. S., Cancer chemoprevention by garlic and garlic-containing sulfur and selenium compounds, J. Nutr. 2006, 136, 864S-869S.
14. Milner, J. A., Preclinical perspectives on garlic and cancer, J. Nutr. 2006, 136, 827S-831S.
15. Rahman, K., Lowe, G. M., Garlic and cardiovascular disease: a critical review, J. Nutr. 2006, 136, 736S-740S.
16. Mathew, P. T., Augusti, K. T., Studies on the effect of Allicin (Diallyl Disulphide-Oxide) on Alloxan Diabetes: Part I-Hypoglycaemic action & enhancement of serum insulin effect & Glycogen synthesis, Indian J. Biochem. Biophys. 1973, 10, 209-212.
17. Grover, J. K., Yadav, S., Vats, V., Medicinal plants of India with anti-diabetic potential, J. Ethnopharmacol. 2002, 81, 81-100.
18. Bailey, C. J., Day, C., Traditional treatments for diabetes, Diabetes Care 1989, 12, 553-564.
19. Sitprija, S., Plengvidhya, C., Kangkaya, V., Bhuvapanich, S., Tunkayoon, M., Garlic and diabetes mellitus phase II clinical trial, J. Med. Assoc. Thai. 1987, 70, 223-227.
20. Ryan, E. A., Pick, M. E., Carceau, C., Use of alternative medicines in diabetes mellitus, Diabet. Med. 2001, 18, 242-245.
21. Bloomgarden, Z. T., American Diabetes Association Annul Meeting, 1999: Type 2 diabetes treatment, Diabetes Care 2000, 23, 405-411.
22. Cicero, A. F. G., Derosa, G., Gaddi, A., What do herbalists suggest to diabetic patients in order to improve glycemic control? Evaluation of scientific evidence and potential risks, Acta Diabetol. 2004, 41, 91-98.
23. Ginsberg, H. N., Investigation os insulin sensitivity in treated subjects with ketosis-prone diabetes mellitus, Diabetes 1977, 26, 278-283.
24. Yki-jarvinen, H., Koivisto, V. A., Natural course of insulin resistance in type 1 diabetes, N. Eng. J. Med. 1986, 315, 224-230.
25. Leslie, R. D. G., Taylor, R., Pozzilli, P., The role of insulin resistance in the natural history of type 1 diabetes, Diabet. Med. 1997, 14, 327-331.
26. Greenbaum, C. J., Insulin resistance in type 1 diabetes, Diabetes Metab. Res. Rev. 2002, 18, 192-200.
27. Anjaneyulu, M., Chopra, K., Nordihydroguairetic acid, a lignin, prevents oxidative stress and the development of diabetic nephropathy in rats, Pharmacol. 2004, 72, 42-50.
28. Liu, C. T., Wong, P. L., Lii, C. K., Hse, H., Sheen, L. Y., Antidiabetic effect of garlic oil but not diallyl disulfide in rats with streptozotocin- induced diabetes, Food Chem. Toxicol. 2006, 44, 1377-1384.
29. El-Demerdash, F. M., Yousef, M. I., Abou El-Naga, N. I., Biochemical study on the hypoglycemic effects of onion and garlic in alloxan-induced diabetic rats, Food Chem. Toxicol. 2005, 43, 57-63.
30. Ding, Y., Zou, R., Judd, R. L., Zhong, J., Effects of gender difference on cardiac myocyte dysfunction in streptozotocin-induced diabetic rats, Endocrine 2006, 29, 135-41.
31. Kobayashi, M., Olefsky, J. M., Effects of streptozotocin-induced diabetes on insulin binding, glucose transport, and intracellular glucose metabolism in isolated rat adipocytes, Diabetes 1979, 28, 87-95.
32. Liu, C. T., Hse, H., Lii, C. K., Chen, P. S., Sheen, L. Y., Effects of Garlic Oil and Diallyl Trisulfide on Glycemic Control in Rats with Streptozotocin-induced Diabetes, Eur. J. Pharmacol. 2005, 516, 165-173.
33. Eidi, A., Eidi, M., Esmaeili, E., Antidiabetic effect of garlic (Allium sativum L.) in normal and streptozotocin-induced diabetic rats, Phytomedicine 2006, 13, 624-629.
34. Jelodar Gholamali, A., Maleki, M., Motadayen, M. H., Sirus, S., Effect of fenugreek, onion and garlic on blood glucose and histopathology of pancreas of alloxan-induced diabetic rats, Indian J. Med. Sci. 2005, 59, 64-69.
35. Baluchnejadmojarad, T., Rohgani, M., Endothelium-dependent and - independent effect of aqueous extract of garlic on vascular reactivity on diabetic rats, Fitoterapia 2003, 74, 630-637.
36. Baluchnejadmojarad, T., Rohgani, M., Garlic extract attenuates time-dependent changes in the reactivity of isolated aorta in streptozotocin-diabetic rats, Life Sci. 2003, 73, 2281-2289.
37. Anwar, M. M., Meki, A. R. M. A., Oxidative stress in streptozotocin- induced diabetic rats: effects of garlic oil and melatonin, Comp. Biochem. Physiol. A 2003, 135, 539-547.
38. Patumraj, S., Tewit, S., Amatyakul, S., Jariyapongskul, A., Comparative effects of garlic and aspirin on diabetic cardiovascular complications, Drug Deliv. 2000, 7, 91-96.
39. Augusti, K. T., Sheela, C. G., Antiperoxide effect of S-allyl cysteine sulfoxide, and secretogogue, in diabetic rats, Experientia 1996, 52, 115-119.
40. Sheela, C. G., Kumud, K., Augusti, K. T., Anti-diabetic effects of onion and garlic sulfoxide amino acids in rats, Planta Med. 1995, 61, 356-357.
41. Roman-Ramos, R., Flores-Saenz, J. L., Alarcon-Aguilar, F. J., Anti-hyperglycemic effect of some edible plants, J. Ethnopharmacol. 1995, 48, 25-32.
42. Swanston-Flatt, S. K., Day, C., Bailey, C. J., Flatt, P. R., Traditional plant treatments for diabetes. Studies in normal and streptozotocin diabetic mice, Diabetologia 1990, 33, 462-464.
43. Farva, D., Goji, I. A., Joseph, P. K., August, K. T., Effects of garlic oil on streptozotocin-diabetic rats maintained on normal and high fat diets, Indian J. Biochem. Biophys. 1986, 23, 24-27.
44. Chang, M. L. W., Johnson, M. A., Effect of garlic on carbohydrate metabolism and lipid synthesis in rats, J. Nutr. 1980, 110, 931-936.
45. Jain, R. C., Vyas, C. R., Garlic in alloxan-induced diabetic rabbits, Am. J Clin. Nutr. 1975, 28, 684-685.
46. Augusti, K. T., Mathew, P. T., Effect of allicin on certain enzymes of liver after a short term feeding to normal rats, Experientia 1975, 31, 148-149.
47. Mathew, P. T., Augusti, K. T., Studies on the effect of allicin (diallyl disulphide-oxide) on alloxan diabetes. I. Hypoglycaemic action and enhancement of serum insulin effect and glycogen synthesis, Indian J. Biochem. Biophys. 1973, 10, 209-121.
48. Jain, R. C., Vyas, C. R., Mahatma, O. P., Hypoglycemic action of onion and garlic, Lancet 1973, 2, 1491.
49. Staba, E. J., Lash, L., Staba, J. E., A commentary on the effects of garlic extraction and formulation on product composition, J. Nutr. 2001, 131, 1118S-1119S.
50. Augusti, K. T., Mathew, P. T., Effect of allicin on certain enzymes of liver after a short term feeding to normal rats. Experientia 1975, 31, 148-149.
51. Sheela, C. G., Augusti, K. T., Antidiabetic effects of S-allyl cysteine sulphoxide isolated from garlic A Ilium sativum Linn, Indian J. Exp. Biol. 1992, 30, 523-526.
52. Geiss, L. S., Herman, W. H., Smith, P. J., National Diabetes-Data Group: Diabetes in America, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 1995, pp. 233-257.
53. Thomson, M., Al-Oattan, K. K., Bordia, T., Ali, M., Including garlic in the diet may help lower blood glucose, cholesterol, and triglycerides, J. Nutr. 2006, 136, 800S-802S.
54. Brace, L. D., Cardiovascular benefits of garlic (Allium sativum L), J. Cardiovasc. Nurs. 2002, 16, 33-49.
55. Ohaeri, O. C., Adoga, G. I., Anticoagulant modulation of blood cells and platelet reactivity by garlic oil in experimental diabetes mellitus, Biosci. Rep. 2006, 26, 1-6.
56. Ashraf, R., Aamir, K., Shaikh, A. R., Ahmed, T., Effects of garlic on dyslipidemia in patients with type 2 diabetes mellitus, J. Ayub Med. Coll. Abbottabad 2005, 17, 60-64.
57. Rossing, P., Hougaard, P., Parving, H. H., Progression of microalbuminuria in type 1 diabetes: ten-year prospective observational study, Kidney Int. 2005, 68, 1446-1450.
58. Parving, H. H., Lewis, J. B., Ravid, M., Remuzzi, G., et al., Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective, Kidney Int. 2006, 69, 2057-2063.
59. Viberti, G. C., Marshall, S., Beech, R., Brown, V., et al., Report on renal disease in diabetes, Diabet. Med. 1996, 13, S6-S12.
60. Forbes, J. M., Cooper, M. E., Oldfield, M. D., Thomas, M. C., Role of advanced glycation end products in diabetic nephropathy, J. Am. Soc. Nephrol. 2003, 14, S254-S258.
61. Mora, C., Navarro, J. F., Inflammation and pathogenesis of diabetic nephropathy, Metabolism 2004, 53, 265-266.
62. Trachtman, H., Futterweit, S., Pine, E., Mann, J., Valderrama, E., Chronic diabetic nephropathy: role of inducible nitric oxide synthase, Pediatr. Nephrol. 2002, 17, 20-29.
63. Ha, H., Kim, K. H., Pathogenesis of diabetic nephropathy: the role of oxidative stress and protein kinase C, Diabetes Res. Clin. Pract. 1999, 45, 147-151.
64. Hotamisligil, G. S., Inflammation and metabolic disorders, Nature 2006, 444, 860-867.
65. Shahab, A., Why does diabetes mellitus increase the risk of cardiovascular disease? Acta Med. Indones. 2006, 38, 33-41.
66. Ramasamy, R., Yan, S. F., Schmidt, A. M., The RAGE Axis and Endothelial Dysfunction: Maladaptive Roles in the Diabetic Vasculature and Beyond, Trends Cardiovasc. Med. 2005, 15, 237-243.
67. Parving, H. H., Osterby, R., Ritz, E., in: Brenner B. M. (Ed.), Brenner and Rector's the Kidney, WB Saunders, Philadelphia 1999, pp. 1831-1883.
68. DeFronzo, R. A., Hendler, R., Simonson, D., Insulin resistance is a prominent feature of insulin-dependent diabetes, Diabetes 1982, 31, 795-781.
69. Maegawa, H., Kobayashi, M., Watanabe, N., Ishibashi, O. et al., Effect of duration of diabetic state on insulin action in isolated rat soleus muscles, Metabolism 1986, 35, 499-504.
70. Munoz, P., Chillaron, J., Camps, M., Castello, A., et al., Evidence for posttranscriptional regulation of glucose transporter 4 expression in muscle and adipose tissue from streptozotocin-induced diabetic and benfluorex-treated rats, Biochem. Pharmacol. 1996, 52, 1665-1673.
71. +-glucose cotransporters, in streptozotocin-induced diabetic rats, Jpn. J. Pharmacol. 2000, 84, 351-354.
72. Cohen, P., in: Drebs, E. G., Boyer, P. D. (Eds), The Enzyme, Academic Press, Orlando, FL, 1987, pp. 462-499.
73. Randle, P. J., Regulatory interactions between lipids and carbohydrates: the glucose fatty acid cycle after 35 years, Diabetes Metab. Rev. 1998, 14, 263-283.
74. Lee, Y., Hirose, H., Ohneda, M., Johnson, J. H., et al., Betacell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-beta-cell relationships, Proc. Natl. Acad. Sci. USA 1994, 91, 10878-10882.
75. Kruszynska, Y. T., McCormack, J. G., McIntyre, N., Effect of glycogen stores and non-esterified fatty acid availability on insulin-stimulated glucose metabolism and tissue pyruvate dehydrogenase activity in the rats, Diabetologia 1991, 34, 205-211.
76. Dutour, A., Mechanisms of glucose toxicity. New hope for prevention of diabetic complications, Eur. J. Endocrinol. 1997, 136, 39-40.
77. Aston-Mourney, K., Proietto, J., Andrikopoulos, S., Investigational agents that protect pancreatic islet beta-cells from failure, Expert Opin. Investig. Drugs 2005, 14, 1241-1250.
78. Hudson, B. I., Schmidt, A. M., RAGE: a novel target for drug intervention in diabetic vascular disease, Pharm. Res. 2004, 21, 1079-1086.
79. Khan, Z. A., Farhangkhoee, H., Chakrabarti, S., Towards newer molecular targets for chronic diabetic complications, Curr. Vasc. Pharmacol. 2006, 4, 45-57.
80. Green, K., Brand, B. D., Murphy, M. P., Prevention of mitochondrial oxidative damage as a therapeutic strategy in diabetes, Diabetes 2004, 53, S110-S118.
81. Ceriello, A., Controlling oxidative stress as a novel molecular approach to protecting the vascular wall in diabetes, Curr. Opin. Lipidol. 2006, 17, 510-518.
82. Bonnefont-Rousselot, D., Bastard, J. P., Jaudon, M. C., Delattre, J., Consequences of the diabetic status on the oxidant/antioxidant balance, Diabetes Metab. 2000, 26, 163-176.
83. Catherwood, M. A., Powell, L. A., Anderson, P., McMaster, D. et al., Glucose-induced oxidative stress in mesangial cells, Kidney Int. 2002, 61, 599-608.
84. Ceriello, A., Oxidative stress and glycemic regulation, Metabolism 2000, 49, 27-29.
85. Bonnefont-Rousselot, D., Glucose and reactive oxygen species, Curr. Opin. Clin. Nutr. Metab. Care 2002, 5, 561-568.
86. Rolo, A. P., Palmeira, C. M., Diabetes and mitochondrial function: role of hyperglycemia and oxidative stress, Toxicol. Appl. Pharmacol. 2006, 212, 167-178.
87. Evans, J. L., Goldfine, I. D., Maddux, B. A., Grodsky, G. M., Are oxidative stress-activated signaling pathways mediators of insulin resistance and β-cell dysfunction? Diabetes 2003, 52, 1-8.
88. Yamagishi, S., Imaizumi, T., Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy, Curr. Pharm. 2005, 11, 2279-2299.
89. Hayden, M. R., Tyagi, S. C., Neural redox stress and remodeling in metabolic syndrome, type 2 diabetes mellitus, and diabetic neuropathy, Med. Sci. Monit. 2004, 10, RA291-RA307.
90. Ho, S. E., Ide, N., Lau, B. H., S-allyl cysteine reduces oxidant load in cells involved in the atherogenic process, Phytomedicine 2001, 8, 39-46.
91. Ide, N., Lau, B. H., Garlic compounds protect vascular endothelial cells from oxidized low density lipoprotein-induced injury, J. Pharm. Pharmacol. 1997, 49, 908-911.
92. Phelps, S., Harris, W. S., Garlic supplementation and lipoprotein oxidation susceptibility, Lipids 1993, 28, 475-477.
93. Sheen, L. Y., Chen, H. W., Kung, Y. L., Liu, C. T., Lii, C. K., Effects of garlic oil and its organosulfur compounds on the activities of hepatic drug-metabolizing and antioxidant enzymes in rats fed high- and low-fat diets, Nutr. Cancer 1999, 35, 160-166.
94. Iqbal, M., Athar, M., Attenuation of iron-nitrilotriacetate (Fe-NTA)-mediated renal oxidative stress, toxicity and hyperproliferative response by the prophylactic treatment of rats with garlic oil, Food Chem. Toxicol. 1998, 36, 485-495.
95. Wu, C. C., Sheen, L. Y., Chen, H. W., Tsai, S. J., Lii, C. K., Effects of organosulfur compounds from garlic oil on the antioxidation system in rat liver and red blood cells, Food Chem. Toxicol. 2001, 39, 563-569.
96. Banerjee, S. K., Maulik, M., Mancahanda, S. C., Dinda, A. K. et al., Dose-dependent induction of endogenous antioxidants in rat heart by chronic administration of garlic, Life Sci. 2002, 70, 1509-1518.
97. Ou, C. C., Tsao, S. M., Lin, M. C., Yin, M. C., Protective action on human LDL against oxidation and glycation by four organosulfur compounds derived from garlic, Lipids 2003, 38, 219-224.
98. Huang, C. N., Horng, J. S., Yin, M. C., Antioxidative and antiglycative effects of six organosulfur compounds in low-density lipoprotein and plasma, J. Agric. Food Chem. 2004, 52, 3674-3678.
99. Maritim, A. C., Sanders, R. A., Watkins, J. B. 3rd., Diabetes, oxidative stress, and antioxidants: a review, J. Biochem. Mol. Toxicol. 2003, 17, 24-38.
100. Marik, P. E., Raghavan, M., Stress-hyperglycemia, insulin and immunomodulation in sepsis, Intensive Care 2004, 30, 748-756.
101. Steppel, J. H., Horton, E. S., Beta-cell failure in the pathogenesis of type 2 diabetes mellitus, Curr. Diab. Rep. 2004, 4, 169-175.
102. Torres, S. H., De Sanctis, J. B., de L Briceno, M., Hernandez, N., Finol, H. J., Inflammation and nitric oxide production in skeletal muscle of type 2 diabetic patients, J Endocrinol. 2004, 181, 419-427.
103. Pickup, J. C., Crook, M. A., Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 1998, 41, 1241-1248.
104. Festa, A., D'Agostino, R., Howard, G., Mykkanen, L., et al., Chronic subclinical inflammation as part of theinsulin resistance syndrom. Circulation, Circulation 2002, 102, 42-47.
105. Pickup, J. C., Chusney, G. D., Thomas, S. M., Burt, D., Plasma interleukin-6, tumour necrosis factor alpha and blood cytokine production in type 2 diabetes, Life Sci. 2000, 67, 291-300.
106. Esposito, K., Nappo, F., Marfella, R., Giugliano, G., et al., Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress, Circulation 2002, 106, 2067-2072.
107. Shanmugam, N., Gaw Gonzalo, I. T., Natarajan, R., Molecular mechanisms of high glucose-induced cyclooxygenase-2 expression in monocytes, Diabetes 2004, 53, 795-802.
108. Shanmugam, N., Reddy, M. A., Guha, M., Natarajan, R., High glucose-induced expression of proinflammatory cytokine and chemokine genes in monocytic cells, Diabetes 2003, 52, 1256-1264.
109. Sandler, S., Bendtzen, K., Eizirik, D. L., Strandell, E., et al., Metabolism and beta-cell function of rat pancreatic islets exposed to human interleukin-1 beta in the presence of a high glucose concentration, Immunol. Lett. 1990, 26, 245-251.
110. Lang, C. H., Dobrescu, C., Bagby, G. J., Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output, Endocrinology 1992, 130, 43-52.
111. Kapur, S., Bedard, S., Marcotte, B., Expression of nitric oxide synthase in skeletal muscle: a novel role for nitric oxide as a modulator of insulin action, Diabetes 1997, 46, 1691-1700.
112. Sprangers, F., Sauerwein, H. P., Romijn, J. A., van Woerkom, G. M., Meijer, A. J., Nitric oxide inhibits glycogen synthesis in isolated rat hepatocytes, Biochem. J. 1998, 330, 1045-1049.
113. Kwon, G., Xu, G., Marshall, C. A., McDaniel, M. L., Tumor necrosis factor alpha-induced pancreatic beta-cell insulin resistance is mediated by nitric oxide and prevented by 15-deoxy-Delta 12, 14-prostaglandin J2 and aminoguanidine. A role for peroxisome proliferator-activated receptor gamma activation and iNOS expression, J. Biol. Chem. 1999, 274, 18702-18708.
114. Aggarwal, B. B., Shishodia, S., Suppression of the Nuclear factor-KB activation pathway by spice-derived phytochemicah, Ann. N.Y. Acad. Sci. 2004, 1030, 434-441.
115. Iwasaki, Y., Kambayashi, M., Asai, M., Yoshida, M., et al., High glucose alone, as well as in combination with proinflammatory cytokines, stimulates nuclear factor kappa-B-mediated transcription in hepatiocytes in vitro, J. Diabetes Complications 2007, 21, 56-62.
116. Tamura, Y., Ogihara, T., Uchida, T., Ikeda, F., et al., Amelioration of glucose tolerance by hepatic inhibition of nuclear factor κB in db/db mice, Diabetologia 2007, 50, 131-141.
117. Ding, H., Li, F., Xu, M., Deng, Y. et al., The effect of inhibiting nuclear factor-kappa B on the diabetic nephropathy, Zhonghua Nei Ke Za Zhi 2002, 41, 605-609.
118. Schmid, H., Boucherot, A., Yasuda, Y., Henger, A., et al., European Renal cDNA Bank (ERCB) consortium. 2006. Modular activation of nuclear factor-kappaB transcriptional programs in human diabetic nephropathy, Diabetes 2006, 55, 2993-3003.
119. Szerafin, T., Erdei, N., Fülöp, T., Pasztor, E. T., et al., Increased cyclooxygenase-2 expression and prostaglandinmediated dilation in coronary arterioles of patients with diabetes mellitus, Circ. Res. 2006, 99, e12-e17.
120. Ali, M., Thomson, M., Afzal, M., Garlic and onions: their effect on eicosanoid metabolism and its clinical relevance, Prostaglandins Leukot. Essent. Fatty Acids 2000, 62, 55-73.
121. Dirsch, V. M., Vollmar, A. M., Ajoene, a natural product with non-steroidal anti-inflammatory drug (NSAID)-like properties? Biochem. Pharmacol. 2001, 61, 587-593.
122. Dirsch, V. M., Kiemer, A. K., Wagner, H., Vollmar, A. M., Effect of allicin and ajoene, two compounds of garlic, on inducible nitric oxide synthase, Atherosclerosis 1998, 139, 333-339.
123. Kim, K. M., Chun, S. B., Koo, M. S., Choi, W. J., et al., Differential regulation of NO availability from macrophages and endothelial cells by the garlic component S-allyl cysteine, Free Radic. Biol. Med. 2001, 30, 747-756.
124. Hodge, G., Hodge, S., Han, P., Allium sativum (garlic) suppresses leukocyte inflammatory cytokine production in vitro: potential therapeutic use in the treatment of inflammatory bowel disease, Cytometry 2002, 48, 209-215.
125. Keiss, H. P., Dirsch, V. M., Hartung, T., Haffner, T., et al., Garlic (Allium sativum L.) modulates cytokine expression in lipopolysaccharide-activated human blood thereby inhibiting NF-kappaB activity, J. Nutr. 2003, 133, 2171-2175.
126. Vlassara, H., Brownlee, M., Cerami, A., Nonenzymatic glycosylation: role in the pathogenesis of diabetic complications, Clin. Chem. 1986, 32, B37-B41.
127. Brownlee, M., in: Rifkin, H., Porte, D. (Eds.), Ellenberg and Rifkin's Diabetes Mellitus, Elsevier Science Publishing Co., New York 1991, p. 279.
128. Lorenzi, M., Montisano, D. F., Toledo, S., Wong, H. C., Increased single strand breaks in DNA of lymphocytes from diabetic subjects, J. Clin. Invest. 1987, 79, 653-656.
129. Lorenzi, M., Montisano, D. F., Toledo, S., Barrieux, A., High glucose induces DNA damage in cultured human endothelial cells, J. Clin. Invest. 1986, 77, 322-325.
130. Baynes, J. W., Thorpe, S. R., Perspectives in diabetes: role of oxidative stress in diabetic complications-a new perspective on an old paradigm, Diabetes 1999, 48, 1-9.
131. El-Seweidy, M. M., El-Swefy, S. E., Ameen, R. S., Hashem, R. M., Effect of age receptor blocker and/or anti-inflammatory coadministration in relation to glycation, oxidative stress and cytokine production in stz diabetic rats, Pharmacol. Res. 2002, 45, 391-398.
132. McKillop, A. M., Abdel-Wahab, Y. H. A., Mooney, M. H., O'Harte, F. P. M., Flatt, P. R., Secretion of glycated insulin from pancreatic beta-cells in diabetes represents a novel aspect of beta-cell dysfunction and glucose toxicity, Diabetes Metab. 2002, 28, 3S61-3S69.
133. Ahmad, M. S., Ahmed, N., Antiglycation properties of aged garlic extract: possible role in prevention of diabetic complications, J. Nutr. 2006, 136, 796S-799S.